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 Homocysteine is a metabolic intermediate in methyl group metabolism that is 
dependent on a number of nutritional B-vitamin cofactors.  An emerging aspect of 
homocysteine metabolism is its relation to health and disease.  Perturbations of 
homocysteine metabolism, particularly intracellular and subsequently circulating 
accumulation of homocysteine (i.e., hyperhomocysteinemia), are associated with vascular 
disease risk, as well as other pathologies.  However, intervention with B-vitamin 
supplementation has been shown to successfully restore normal homocysteine 
concentrations, but without concomitant reductions in disease risk.  Thus, the mechanistic 
relation between homocysteine balance and disease states, as well as the value of 
homocysteine management, remains an area of intense investigation. 
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 Homocysteine is an amino acid generated metabolically by the S-
adenosylmethionine (SAM)-dependent transmethylation pathway (1).  This series of 
reaction occurs in most cells and tissues; however, the liver is the most prominent site for 
SAM-dependent transmethylation and the subsequent production of homocysteine.  As 
shown in Fig. 1, the initial step is the activation of methionine to SAM by the ATP-
dependent action of methionine adenosyltransferase.  SAM is the universal methyl donor 
for numerous transmethylation reactions, including the methylation of proteins, nucleic 
acids, lipids, and small molecule substrates such as amino acids.  A consequence of all 
SAM-dependent transmethylation reactions is the subsequent generation of S-
adenosylhomocysteine (SAH), which is then hydrolyzed to adenosine and homocysteine 
by SAH hydrolase.  It is important to note that the intracellular concentrations of SAM and 
SAH are critically important with respect to regulating methylation reactions, as SAH is an 
allosteric inhibitor of most methyltransferases (2).  Thus, the ratio of SAM/SAH can be 
viewed as an index of transmethylation potential in the cell (3,4). 
 Following the production of homocysteine by SAM-dependent transmethylation, it 
can undergo remethylation back to methionine, or be irreversibly catabolized by the 
transsulfuration pathway.  Two tissue-specific homocysteine remethylation pathways are 
known to exist: a folate-dependent reaction that utilizes 5-methyltetrahydrofolate (5-CH3-
THF) as a substrate and the action of the B12-dependent enzyme methionine synthase 
(MS);  and a folate-independent route catalyzed by betaine-homocysteine S-
methyltransferase (BHMT) where betaine, an oxidation product of choline, serves as the 
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methyl donor.  Hepatic BHMT and MS are considered to contribute equally in the process 
of homocysteine remethylation in the liver (5).   For both reactions, the homocysteine 
backbone of methionine serves as an acceptor of methyl groups for the maintenance of 
essential SAM-dependent transmethylation reactions.  Transsulfuration is an alternative 
and essential route for homocysteine catabolism that is initiated by the action of 
cystathionine β-synthase (CBS), a B6-dependent enzyme, to form cystathionine via the 
condensation of homocysteine and serine.  Cystathionine is further metabolized by γ-
cystathionase to cysteine, a conditionally essential amino acid that, in addition to protein 
synthesis, is required for the synthesis of glutathione and other biologically important 
molecules such as taurine.  Thus, homocysteine balance is dependent on the numerous 
SAM-dependent transmethylation reactions that result in its production, counterbalanced 
with the utilization of homocysteine for folate-dependent/ -independent remethylation and/ 
or transsulfuration.  Some of the specific enzymes and regulatory proteins involved in 
homocysteine production and utilization are addressed further in the following sections. 
 
Homocysteine Production:  SAM-dependent Transmethylation and Regulation of 
Homocysteine Balance 
 As there are >100 SAM-dependent transmethylation reactions, all contributing to 
intracellular homocysteine pools, it is beyond the scope of this review to adequately 
address even the most critical reactions.  However, it is important to recognize and discuss 
the transmethylation reactions that are thought to contribute the greatest extent to 
homocysteine production, as well as have a potential regulatory role.  Collectively, the 
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hepatic production of phosphatidylcholine (PC) and creatine, catalyzed by the SAM-
dependent enzymes phosphatidylethanolamine N-methyltransferase (PEMT) and 
guanidinoacetate N-methyltransferase (GAMT), respectively, represent the greatest usage 
of methyl groups (~85%) from SAM (6,7); thus, the action of PEMT and GAMT are major 
determinants of homocysteine production.  The synthesis of PC is important in the 
maintenance of cell membranes and lipoproteins, and methylation of guanidinoacetate is 
the final step in the synthesis of creatine, a key molecule in energy metabolism as creatine 
phosphate.  Traditionally, GAMT was considered the most significant consumer of methyl 
groups from SAM; however, this hypothesis has been recently challenged, as the reaction 
catalyzed by PEMT requires 3 methyl groups from SAM in the conversion of 
phosphatidylethanolamine (PE) to PC (8,9).  
In addition to the specific reactions PEMT and GAMT function to catalyze, they 
have also been proposed to have a regulatory role with respect to homocysteine balance.  
For hepatic creatine synthesis, it has been shown that decreasing the demand for SAM-
dependent methylation of guanidinoacetate by GAMT via dietary supplementation with 
creatine resulted in a significant decrease in homocysteine concentrations (10).  
Conversely, the production of homocysteine was elevated owing to the dietary provision of 
guanidinoacetate.  Thus, the demand that creatine synthesis places on hepatic 
homocysteine production has a major impact on homocysteine balance, as reflected in the 
circulating concentrations of homocysteine. 
 SAM-dependent methylation of PE to generate PC is a vital component in the 
maintenance of normal VLD production such that when compromised, the result is hepatic 
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steatosis owing to an inability to export fatty acids from the liver (11).  In addition to 
lipoprotein synthesis, Vance and coworkers have shown that PEMT is a key regulator of 
homocysteine balance (12,13).  Using PEMT -/- knockout mice, the lack of PEMT 
expression significantly reduced the circulating concentrations of homocysteine, whereas 
its over-expression resulted in hyperhomocysteinemia.  Thus, the expression and activity 
of PEMT appears to be directly correlated to homocysteine accumulation.  
 A third key enzyme in SAM-dependent methyl group metabolism is glycine N-
methyltransferase (GNMT), a protein which regulates the supply and utilization of methyl 
groups, particularly with respect to methyl groups supplied by the folate-dependent 
pathway (14).  Owing to its significant intracellular abundance (1-2% of soluble cytosolic 
protein) and regulatory role in maintaining an optimal ratio of SAM: SAH, it would be 
expected that regulation of GNMT expression and function would translate into having a 
direct impact on homocysteine balance, similar to that exhibited by PEMT.  However, to 
date this has not been clearly demonstrated.  A GNMT knockout mouse model was 
characterized by extremely high levels of methionine and SAM in the circulation (15); 
however, plasma homocysteine concentrations were not reported.  Although over-
expression of GNMT might be expected to result in excessive production of homocysteine, 
various rodent models exhibiting a marked increase in GNMT abundance and activity did 
not translate into similar changes in the circulating concentrations of homocysteine (16-
19).  In fact, homocysteine concentrations were actually diminished in these studies, owing 
to the increased activity of other enzymes involved in homocysteine remethylation and 
catabolism.  
   




Homocysteine Utilization:  Remethylation and Transsulfuration 
 Similar to the SAM-dependent transmethylation enzymes discussed earlier, 
enzymes involved in the metabolism of homocysteine, by either remethylation or 
transsulfuration, also have a significant impact on homocysteine balance.  Consequently, 
these three routes for homocysteine metabolism represent an additional point for its 
regulation. 
 For folate-dependent remethylation of homocysteine by the B12-dependent enzyme 
MS, much of the data regarding the impact of this pathway on homocysteine balance 
resides in studies focused on the polymorphic expression of the enzyme 5,10-
methylenetetrahydrofoalte reductase (MTHFR).  For humans, a reduction in the activity of 
MTHFR owing to the single nucleotide polymorphism C677T has been associated with 
hyperhomocysteinemia and vascular disease (20-22).  Similarly, MTHFR-deficient mice 
exhibited hyperhomocysteinemia, as well as indicators of neurological and vascular 
problems (23).  For all cases of reduced MTHFR function, the ensuing 
hyperhomocysteinemia can be attributed to the compromised ability of the folate/ B12-
dependent pathway to adequately remethylate homocysteine and is most pronounced under 
conditions of low folate intake.  Because the MTHFR C677T genotype represents a 
significant determinant in circulating homocysteine concentrations, its presence is also 
linked to the potential disease risks associated with hyperhomocysteinemia.  Moreover, a 
clear interaction exists between populations that exhibit the MTHFR C677T genotype in 
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combination with polymorphisms of other enzymes involved in homocysteine balance, 
including the PEMT G5465A, the GNMT C1289Y, and the MS A66G genotypes (24-26).   
For folate-independent homocysteine remethylation using betaine as a methyl 
donor, BHMT has been shown to be a key regulator of homocysteine balance, particularly 
under diabetic conditions (16,17,27) and in response to dietary protein supply (28,29).  To 
date, a rodent BHMT knockout model has not been developed as a means to further 
understand the relation between BHMT expression and homocysteine balance.  However, 
the development of specific and potent inhibitors of BHMT has provided insight its role in 
regulating homocysteine metabolism.  Mice administered S-(δ-carboxybutyl)-DL-
homocysteine (CBHcy) as a means to knockdown BHMT function lowered BHMT activity 
nearly 90% and increased plasma total homocysteine concentrations 7-fold (30).  This 
relation between BHMT and circulating homocysteine concentrations appears to be highly 
specific, as CBHcy treatment was without effect on the enzymatic activities of MS, 
MTHFR, or PEMT (Garrow, T., personal communication). 
A key enzyme in the irreversible catabolism of homocysteine is CBS, the B6-
dependent enzyme that catalyzes the initial condensation of serine and homocysteine to 
form cystathionine.  The earliest evidence linking aberrant homocysteine metabolism (i.e., 
hyperhomocysteinemia) to cardiovascular disease results from the observations noted in 
humans exhibiting a lack of sufficient CBS expression, namely homocystinuria (31).  
Using a transgenic mouse model, Wang et al. (32) has demonstrated that induction of 
hepatic and renal CBS effectively lowered serum homocysteine concentrations.  In support 
of these observations, the inherent elevation of CBS expression in diabetic rat models was 
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associated with a state of hypohomocysteinemia, owing to elevated homocysteine 
catabolism via the transsulfuration pathway (33).  
In summary, a number of key enzymes involved in homocysteine metabolism play 
a pivotal role in homocysteine balance.  It should be noted that a variety of other factors 
impact the regulation and function of these enzymes, including diet, age, physiological 
state, and hormonal imbalance.  Moreover, and in addition to the MTHFR C677T 
polymorphisms, the majority of these enzyme proteins exhibit polymorphic forms that 
certainly have the potential to impact homocysteine balance for specific individuals, as has 
been discussed.  For humans, the most sensitive individuals for aberrant homocysteine 
metabolism are likely characterized by exhibiting multiple determinants.  
 
Hyperhomocysteinemia: relation between homocysteine balance and disease 
 Hyperhomocysteinemia, the accumulation of homocysteine in the circulation, has 
received considerable attention in the last decade with respect to a number of disease states 
in both animal models and human studies.  The predominant focus has been on 
hyperhomocysteinemia being recognized as an independent risk factor for cardiovascular 
disease (34,35).  It has been estimated that a 2.5 µM rise in circulating homocysteine 
concentrations translates into a 10% increase in cardiovascular disease risk.  This relation 
between homocysteine concentrations and cardiovascular disease risk has since been 
extended to include other vascular diseases as well (36).  Moreover, 
hyperhomocysteinemia has been reported to be a potential risk factor in a number of other 
pathologies, including diabetes, birth defects, neurological disorders, and  cancer 
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development (37-40).  A key issue that remains to be resolved is whether a condition of 
hyperhomocysteinemia has a direct, causal impact on vascular disease, or exists as a 
biomarker that reflects another mechanistic basis for the adverse effects on vascular 
function.  
 
Intervention studies to reduce elevations in homocysteine concentrations 
 Based on the preceding discussion, it is a logical approach to expect that dietary 
intervention to reduce circulating homocysteine concentrations represents a viable means 
to subsequently reduce cardiovascular disease risk.  There have been numerous 
investigations into the impact of homocysteine-lowering treatment with B vitamins for the 
prevention of vascular disease.  To date, most studies have demonstrated that treatment 
with folic acid, B12, B6 or a combination thereof results in a significant decrease in plasma 
homocysteine.  Whether this lowering of plasma homocysteine is associated with a 
reduction in the incidence of disease via B-vitamin therapies remains controversial (41,42).   
Near the turn of the century, the evidence from several trials suggested that B-
vitamin treatment could decrease the risk of vascular diseases, but subsequent 
investigations were not as promising.  Early studies showed improved B-vitamin status 
lowered plasma homocysteine levels, and decreased incidence of adverse events or 
improvements in indicators of vascular endothelial dysfunction in patients treated with 
folic acid, B12, and/or B6 vs. those treated with a placebo (43-47).  However, these results 
have largely been refuted by the predominantly negative results of subsequent trials, 
including the NORVIT, WENBIT, HOPE-2, VISP, VITATOPS, and VITRO studies (48-
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60).   These studies generally had a mean follow-up time of several years and assessed a 
wide variety of vascular indicators and endpoints including carotid intima-media thickness 
and flow-mediated dilation (52), markers of arterial inflammation (49-58), need for 
revascularization procedures (54), occurrence of thromboembolism (53,55), occurrence of 
stroke and myocardial infarction (48,50,54,56,57,59), as well as overall or 
coronary/vascular-related mortality (48,50,51,54,56,59).     
It is not clear as to what factors may account for the disparity in these findings.  
The duration of treatment, B-vitamin status, and polymorphisms of enzymes involved in 
homocysteine metabolism could potentially play a role.  Notably, the treatment period was 
generally longer in duration for the later studies in comparison to those conducted earlier, 
i.e. several years vs. weeks or months.  The apparent affect of the duration of treatment is 
supported by the meta-analysis by Potter et al (52) in which they found that in patients 
post-stroke, B-vitamin treatment had positive effects in the short term, but these effects 
were not sustained long term.  Research in this area is ongoing and several recent short 
term studies have demonstrated benefits of folate supplementation alone on vascular 
outcomes in high-risk patients (61-63).   Interestingly, the data suggests that improvements 
are independent of the homocysteine-lowering effect of treatment, therefore other 
mechanisms of action should also be considered for short-term treatment effects..  More 
data is also expected from additional long-term studies of high-risk populations which 
have been initiated, but are not yet complete (64,65).  Although poor B-vitamin status and 
polymorphisms of MTHFR have been associated with elevations in plasma homocysteine 
levels and may impact the homocysteine-lowering response to treatment, there is little or 
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no evidence to support that these factors may account for differential results between 
studies. 
Vascular diseases are not the only conditions in which there have been trials of B-vitamin 
interventions.   Unfortunately, there appears to be no effect of homocysteine-lowering B-
vitamin therapy on Alzheimer’s disease and cognitive decline (66-68) or type 2 diabetes 
(69), and the results are conflicting regarding potential effects on bone mineral density and 
turnover, and fracture occurrence (70-72).  However, not all findings have been negative; 
the Women’s Antioxidant and Folic Acid Cardiovascular Study found that long-term daily 
treatment with folic acid, pyridoxine, and cobalamin in a high-risk population reduced the 
risk of age-related macular degeneration (73).  Furthermore, studies in healthy individuals 
suggest that treatment with B vitamins may be an effective means of reducing the risk of 
stroke (74) and slowing the progression of early-stage atherosclerosis (75).   Though the 
data is limited, the most important research area for the future use of treatments with the 
homocysteine-lowering vitamins is the identification of which specific populations are 
most expected to benefit from therapy, with particular emphasis on primary prevention. 
 
Summary 
 Because of the association of hyperhomocysteinemia with a number of pathological 
conditions, particularly vascular disease, it is clear that homocysteine management 
represents a significant focus for nutrition and health.  Supplementation with the various 
B-vitamin cofactors that are essential to maintain homocysteine balance represents the 
most logical and viable approach.  However, much remains to be resolved to understand 
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the mechanistic relation between homocysteine imbalance and disease, and subsequently 
the most appropriate approach to maintain homocysteine balance as a means to reduce 
disease risk.  It will also be of utmost importance to identify specific populations that are 
most sensitive to homocysteine imbalance, based on known polymorphisms or 
physiological states that have been shown to impact homocysteine metabolism. 
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 Fig. 1.  Hepatic folate, methyl group, and homocysteine metabolism. 
Abbreviations of metabolites and enzymes are: betaine-homocysteine S-methyltransferase 
(BHMT); cystathionine β-synthase (CBS); cystathionine γ-lyase (CGL); dimethylglycine 
(DMG); methionine synthase (MS); methyltransferases (MTs); 5,10-methylene-THF 
reductase (MTHFR); S-adenosylhomocysteine (SAH); S-adenosylmethionine (SAM); 
serine hydroxymethyltransferase (SHMT); tetrahydrofolate (THF); and methyl acceptor 
(X).  For this review, important SAM-dependent methyltransferases include: glycine N-
methyltransferase (GNMT); guanidinoacetate N-methyltransferase (GAMT); and 
phosphatidylethanolamine N-methyltransferase (PEMT).  These three methyltransferases 
respectively catalyze the conversion of glycine to sarcosine, guanidinoacetate to creatine, 
and phosphatidylethanolamine (PE) to phosphatidylcholine (PC).  In addition to folate, 
note that this series of interrelated pathways are dependent on a number of other B-
vitamins, including riboflavin (B2), vitamin B6, and vitamin B12. 
 
 
 
 
 
 
